NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Co-Founder and Chief Scientific Officer Renรฉ Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrintยฎ, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment ย Irvine, California and Amsterdam, Netherlands, May 07, 2020 Read More
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ MARCH 31, 2020 โ Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and assure you that we are monitoring the situation regarding the outbreak of Corona Virus Disease (COVID-19) very closely; your patientโs sample and the safety of Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ February 13, 2020 โ Agendia, Read More
Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van โt Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 17 January 2020 โ Laura Read More
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrintยฎ Testing through Techniker Krankenkasse
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrintยฎ Testing through Techniker Krankenkasse ย IRVINE, CALIF., U.S. and Amsterdam โ 3 January 2020 โ Agendia Inc., a world leader in precision Read More
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, December 12, 2019 โ Agendia, Inc., a world leader in precision oncology for Read More